>> is anyone invested here or just thinking about it. <<
Many of those here who know this company best are also those most familiar with the lack of premium that was assigned to platforms and intellectual property, as recently as Spring '99.
Fun, visionary stuff, and I personally believe that there will be a rush to shove target validation into a narrow funnel. That is, I believe that a decent assignment of value will hang in there for validation platforms.
But.... you go first, and tell us how the water is.
I had a chance to work with Lamphier in the early days of biotech, when he was running Business Development for Biotherapeutics in Franklin, TN. They went belly up.
Not his fault, however. Tough business model.... Oldham's attempt to tailor biological therapy to the individual patient. Pioneering thoughts, but pharma and health care weren't ready for the concept. Ironically, neither was the biologist..... the early attempts focused increasingly on IL-2 for renal carcinoma (as attempts to tailor MAbs to a given patient failed). Ugly toxicity. Got to talk, bedside, with the first big-time responder to the therapy. Thankful guy, but he also talked about the fevers, nausea, and other more disturbing stuff ass'd with infusions.
Anyway, that effort doesn't reflect, IMO, on Lamphier. I was very impressed with the guy, and bent over backwards to collaborate with the company (bispecific monoclonals, anti-tumor and anti-CD2).
Another aside.... that's where I started to follow the Baxter efforts with cellular immunology, which largely evolved into the modern day NEXL effort. Baxter was collaborating with Biotherapeutics.
Ahead of their time. Unfortunately, we may not even be there yet.
<pg> |
